Acute kidney injury after coronary artery bypass grafting and outcomes by Rydén, Linda
From the Department of Medicine Solna 
Karolinska Institutet, Stockholm, Sweden 









All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-­‐print	  AB	  
© Linda Rydén, 2015 
ISBN 978-91-7549-777-8  
	  	  
	  
	  Institutionen	  för	  Medicin	  Solna	  
	  
ACUTE	  KIDNEY	  INJURY	  AFTER	  CORONARY	  	  	  
ARTERY	  BYPASS	  GRAFTING	  AND	  OUTCOMES	  AKADEMISK	  AVHANDLING	  som	  för	  avläggande	  av	  medicine	  doktorsexamen	  vid	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Karolinska	  Institutet	  offentligen	  försvaras	  i	  Nanna	  Svartz	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Auditorium,	  Karolinska	  Universitetessjukhuset	  Solna	  
Fredagen	  den	  6	  mars	  2015	  kl	  09.00	  Av	  	  Linda	  Rydén	  	  Leg.	  läk.	  
	  
Huvudhandledare:	  Docent	  Martin	  J.	  Holzmann	  Karolinska	  Institutet	  Institutionen	  för	  Medicin	  Solna	  Enheten	  för	  Klinisk	  Epidemiologi	  	  
Bihandledare:	  Professor	  Staffan	  Ahnve	  Karolinska	  Institutet	  Institutionen	  för	  Folkhälsa	  	  Med.	  Dr	  Max	  Bell	  Karolinska	  Institutet	  Institutionen	  för	  Fysiologi	  och	  Farmakologi	  Sektionen	  för	  Anestesi	  och	  Intensivvård	  	  Professor	  Torbjörn	  Ivert	  Karolinska	  Institutet	  Institutionen	  för	  Molekylär	  	  Medicin	  och	  Kirurgi	  Sektionen	  för	  Thoraxkirurgi	  	  
Stockholm	  2015	  
Fakultetsopponent:	  Professor	  Norbert	  Lameire	  Gent	  University	  Hospital	  Gent,	  Belgium	  	  
Betygsnämnd:	  Docent	  Peter	  Bárány	  Karolinska	  Institutet	  Institutionen	  för	  Klinisk	  Vetenskap,	  	  Intervention	  och	  Teknik	  	  Docent	  Göran	  Dellgren	  Sahlgrenska	  Akademin	  Göteborgs	  Universitet	  Institutionen	  för	  Medicin	  Avdelningen	  för	  Molekylär	  och	  	  Klinisk	  Medicin	  	  Docent	  Ylva	  Trolle	  Lagerros	  Karolinska	  Institutet	  Institutionen	  för	  Medicin	  Solna	  Enheten	  för	  Klinisk	  Epidemiologi	  	  	  
Linda Rydén 
 






































TO CHARLES & CHANELLE

   Abstract
  
ABSTRACT	  
Acute kidney injury (AKI) is a rapid reduction in glomerular filtration rate (GFR) that leads 
to a rise in serum creatinine (SCr). Acute kidney injury is common and patients with sepsis 
and patients who undergo cardiac surgery are at highest risk. Acute kidney injury is a 
potentially life-threatening complication that affects 9–40% of patients who undergo 
coronary artery bypass grafting (CABG). The associations between AKI and postoperative 
complications, long-term myocardial infarction (MI) risk, stroke and end-stage renal disease 
(ESRD) are not well described. The overall aims of this thesis are to study the associations 
between AKI after CABG and postoperative complications, short- and long-term mortality, 
long-term MI risk, stroke and ESRD. 
Study I investigated the association between AKI after an initial isolated CABG and 
postoperative complications and death within 60 days of surgery. Of 7594 patients, 1047 
(14%) patients developed AKI as defined by the Acute Kidney Injury Network (AKIN) 
classification. Patients with AKI had increased risk for death and postoperative 
complications. Multivariable adjusted odds ratios (OR) with 95% confidence intervals (CI) in 
patients in AKIN stage 1 compared with patients without AKI were 4.36 (95% CI: 2.83–6.71) 
for short-term mortality; 2.34 (1.43–3.82) for stroke; and 2.88 (1.84–4.50) for mediastinitis 
compared with patients without AKI.  
Studies II-IV investigated associations between AKI and long-term risks for mortality, MI, 
stroke or ESRD in a nation-wide cohort of almost 30 000 patients who underwent first 
elective CABG, 13% of whom developed AKI postoperatively. Associations were seen 
between MI, mortality and AKI, with hazard ratios (HR) for MI and death increasing with 
AKI severity. Adjusted HR for patients with AKI stage 1 were 2.92 (95% CI: 1.87–4.55) for 
ESRD; 1.35 (95% CI: 1.15–1.57) for MI; and 1.30 (95% CI: 1.17–1.44) for all-cause 
mortality compared with patients without AKI. Although we found no association between 
AKI and long-term risk of stroke, a subgroup analysis showed an increased long-term risk for 
postoperative stroke among patients younger than 65 years. 
In conclusion, AKI after CABG was associated with increased risks for postoperative death, 
stroke, and mediastinitis. AKI was also strongly associated with long-term mortality, MI and 
ESRD after CABG, but not with long-term risk of stroke. 
Key words: Acute Kidney Injury, Coronary Artery Bypass Grafting, Stroke, End-stage Renal Disease, 
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Acute kidney injury (AKI) is defined as an abrupt decrease in the kidneys´ ability to filter 
waste products, thus leading to increased blood levels of metabolites such as creatinine. The 
incidence of AKI is increasing worldwide.1 Acute kidney injury affects patients in all clinical 
settings but is most prevalent among septic patients in the intensive care unit (ICU) and 
among patients after cardiovascular surgery.1-3 
Over the last decade, even very small increases in serum creatinine (SCr) have been shown to 
be associated with adverse outcomes in hospitalized patients.4, 5  
Coronary artery disease (CAD) is widespread, and is the main cause of death in Sweden.6 
Coronary artery bypass grafting (CABG) is an efficient treatment for patients with 
obstructive CAD and is associated with better survival among high-risk patients compared 
with medication or percutaneous coronary intervention (PCI).7 Because of this, and in 
combination with improved surgical and anesthetic skills, older and more fragile patients 
have been undergoing CABG. This has led to an increasing number of postoperative 
complications.8  
This thesis aims to elucidate the effects of AKI, including small changes of creatinine levels 
after CABG, and the risks for postoperative complications, short and long-term mortality, 


























DEFINITION	  OF	  ACUTE	  KIDNEY	  INJURY	  
Acute kidney injury is a rapid reduction in glomerular filtration rate (GFR) that leads to a rise 
in SCr.1 It is a common complication in various clinical settings. About 1–5% of hospitalized 
general surgical and medical patients are affected by AKI.9 Acute kidney injury is associated 
with adverse outcomes and high health care costs.10, 11 The most common cause of AKI is 
sepsis, which affects up to 70% of septic ICU patients.12, 13 However, patients who undergo 
cardiac surgery have also been shown to be at great risk for AKI.10, 14  
The term “acute renal failure” (ARF) was used until 2004 for cases when a patient´s GFR 
suddenly decreased. However, ARF had no standard definition at that time. More than 35 
different definitions of ARF were reported in the literature, ranging from a small increase in 
SCr to renal failure requiring dialysis.10, 15, 16 In a systematic review of 28 studies of 
preoperative risk factors for postoperative ARF, 26 different definitions were used.17 This 
made comparison of outcomes from different studies impossible. Patients with ARF after 
extensive surgery, especially those in need of dialysis, were known to have increased risk of 
postoperative mortality.15, 18 From 2004 to 2006, several studies found associations between 
small changes in postoperative SCr levels and increased postoperative risk of death.4, 5, 12 
	   	  
Risk,	   Injury,	   Failure,	   Loss	   of	   Kidney	   Function,	   End-­‐stage	   Renal	   Disease	  
classification	  
In 2004, the Acute Dialysis Quality Initiative introduced a new common classification of AKI 
called RIFLE (Table 1). This classification was based on acute elevations of SCr levels to 
various degrees or sudden decreases in estimated glomerular filtration rate (eGFR), compared 
with baseline levels of SCr or GFR, or a change in urine output over a specified time period. 
The term ARF was then replaced by the term AKI. RIFLE defines AKI by three different 
degrees of severity (R–Renal risk, I– Injury, F-Failure) and two outcomes (L– Loss of kidney 
function, E– End-stage renal disease).19 The RIFLE classification has been validated in 






RIFLE criteria improved the definition of AKI and made measurement and comparison of 
outcomes after AKI much better, RIFLE had some limitations– for example, whether urine 
output criteria should be used or not; and whether changes in eGFR were a preferable metric 
than SCr. When urinary output criteria are used, the patient needs a urinary catheter, and 
urine output is often under the influence of diuretics. Estimated GFR is known to not be 
reliable in a situation without steady state.22-24 Baseline SCr is missing in some studies, which 
makes classification impossible.22 To handle missing baseline SCr values, some have 
suggested that they may be calculated backwards from the Modification of Diet in Renal 
Disease (MDRD) formula;25 this might give very uncertain estimates.26-28  
	  
Acute	  Kidney	  Injury	  Network	  classification	  
In 2007, the Acute Kidney Injury Network (AKIN) modified the RIFLE criteria. An absolute 
increase of 26.5 µmol/L (0.3 mg/dL) in SCr levels and a time interval of 48 hours when the 
increase should occur were added to the classification (Table 1). This classification was 
named the AKIN criteria.29 In addition the eGFR criteria and the two outcome categories 
were abandoned. Finally, they allocated patients with AKI who required dialysis to stage 3 
despite the severity of their AKI.29 The AKIN criteria also recommend that AKI should only 
be diagnosed after adequate volume resuscitation, and that post-renal obstruction would need 
to be excluded if oliguria was present.  
Acute kidney injury has also been classified in three groups by absolute numbers in some 
studies, for example, SCr rising from baseline by 0.3–0.5, 0.5–1.0 or >1.0 mg/dL.5, 30, 31 This 
is based on the AKIN definition and is thought to be easier to use in clinical practice. 













Table 1. The RIFLE19 and AKIN29 criteria. Acute kidney injury should occur within 1 week for RIFLE 
and within 48 hours for AKIN. 
Stage Increase in serum creatinine from baseline Urine output criteria 
RIFLE 
Risk × 1.5 or GFR decrease >25%  <0.5 mL/kg/h for ≥6 h 
Injury × 2 or GFR decrease >50% <0.5 mL/kg/h for ≥12 h 
Failure × 3 or GFR decrease >75% or baseline SCr ≥4 mg/dL  
(≥354 µmol/L) with an acute rise of ≥0.5 mg/dL  
(≥44.2 µmol/L)  
<0.3 mL/kg/h for ≥24 h  
or anuria ≥12 h 
Loss of Kidney 
Function 
Complete loss of renal function >4 weeks  
End-stage 
Renal Disease 
End-stage renal disease (>3 months)  
AKIN 
Stage 1 ≥0.3 mg/dL (≥26.5 µmol/L) or 150% to 200% (1.5- to 2-
fold)  
<0.5 mL/kg/h for ≥6 h 
Stage 2 >200% to 300% (>2- to 3-fold) <0.5 mL/kg/h for ≥12 h 
Stage 3 >300% (>3-fold) or ≥0.5 mg/dL (≥44 µmol/L) if baseline  
SCr is ≥4.0 mg/dL (≥354 µmol/L).  
Patients on renal replacement therapy are considered in 
stage 3. 
<0.3 mL/kg/h for ≥24 h  
or anuria ≥12 h  
RIFLE, Risk, Injury, Failure, Loss of kidney function, End-stage renal disease; AKIN, Acute Kidney Injury 
Network; AKI, acute kidney injury; SCr, serum creatinine; GFR, glomerular filtration rate. 
	  
Kidney	  Disease:	  Improving	  Global	  Outcomes	  guidelines	  
Kidney Disease: Improving Global Outcomes (KDIGO) is an international group of experts 
who work to improve treatment for kidney diseases.1 As KDIGO wanted a unified definition 
for AKI, they merged the AKIN and RIFLE criteria. Their definition for stage 1 AKI did not 
change in terms of absolute increases by SCr levels of 26.5 µmol/L (0.3 mg/dL) within 48 
hours compared with AKIN. However, for the 50% increase in SCr levels from baseline, the 
defining time interval was changed to 7 days, as in RIFLE (Table 2).33  
 
Table 2. The Kidney Diseases: Improving Global Outcomes (KDIGO) guidelines for definition of acute 
kidney injury.33 Increase in serum creatinine ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours or ≥1.5 times 
baseline, within the prior 7 days. 
Stage Serum Creatinine Urine Output 
1 1.5–1.9 × baseline or ≥0.3 mg/dL (≥26.5 µmol/L) increase  <0.5 mL/kg/h for 6–12 h 
2 2.0–2.9 × baseline 
 
<0.5 mL/kg/h for ≥12 h 
3 3 × baseline or increase in SCr to ≥4.0 mg/dL (≥354 µmol/L) 
or initiation of renal replacement therapy 
or in patients <18 years a decrease in eGFR to <35 mL/min/1.73 m2 
<0.3 mL/kg/h for ≥24 h or 
anuria ≥12 h 






The three main AKI classification systems have been compared in several articles. In studies 
of general ICU populations the RIFLE classification presented a higher incidence of AKI 
than did AKIN;34, 35 however, the highest incidence occurred with the KDIGO 
classification.35 Luo et al. showed higher mortality among patients in the AKIN group than in 
the KDIGO group (32% vs. 27%, P = 0.006),35 whereas in AKI-related mortality did not 
significantly differ between RIFLE and KDIGO (P = 0.815).35  
A Brazilian study of 169 patients who underwent CABG, showed a high incidence of AKI; 
33% classified by AKIN and 30% by RIFLE. The mortality in the two groups was similar 
and the authors concluded that the AKIN and RIFLE classifications accord well in 
detecting AKI after CABG.36 Bastin et al. classified 1881 adults undergoing cardiac 
surgery by AKIN, RIFLE and KDIGO criteria and found similar AKI incidences with 
AKIN and RIFLE; however receiver operator characteristic (ROC) analysis of in-hospital 
mortality favored AKIN (0.86 vs. 0.78, P = 0.0009). The incidence and outcome between 
AKIN and KDIGO were identical.37  
 
INCIDENCE	  AND	  OUTCOMES	  OF	  ACUTE	  KIDNEY	  INJURY	  	  
The incidence of AKI is increasing all over the world. Approximately 600,000 cases of AKI 
are reported in the United States every year and the incidence of AKI that require dialysis 
increases by >7% every year.38, 39 This has several explanations. Consensus criteria like 
RIFLE and AKIN have improved diagnosis of AKI, the condition is more recognized, and 
several patient-related factors contribute to the increase, including an ageing population.40 
Increasing and extensive use of nephrotoxic drugs in diagnostic and treatment procedures 
could also explain this trend.41 
In a meta-analysis of 312 studies concerning the world incidence of AKI, the authors found 
that among critically ill patients, one out of five adults and one out of three children 
developed AKI during hospitalization.42  
The incidence of AKI varies in different settings. It is most common among ICU patients 
with sepsis, and after cardiac surgery. Li et al. found that in 64 patients who underwent 
elective CABG, 20% developed AKI (stage 1: 7.9%; stage 2: 3.5%; stage 3: 8.4%). It was 
highly prevalent in patients with diabetes mellitus (DM), 56%.43 In a Swedish cohort of 
patients who underwent isolated CABG, early mortality was seen in 3.6% and long-term 





mortality in 12% of isolated CABG patients.44 Among patients with AKI after cardiac 
surgery, 11% died within 1 year and 56% within 10 years.45  
 
RISK	  FACTORS	  FOR	  ACUTE	  KIDNEY	  INJURY	  
Several factors are associated with the development of AKI. Sepsis is the most common 
cause, followed by cardiac surgery.46-48 Critical illness, burns, trauma, and exposure to radio 
contrast material are other frequently described causes.33, 40, 49 However, the individual 
patient´s susceptibility determines whether an exposure will lead to AKI. Dehydration, 
congestive heart failure, advanced age, chronic kidney disease (CKD), anemia and DM are 
examples of potential predisposing factors.33 Although more than one third of AKI cases are 
reportedly community-acquired,33 community-acquired AKI (CA-AKI) is not widely studied. 
In a worldwide meta-analysis of AKI, defined using a KDIGO equivalent, CA-AKI was 
compared with hospital acquired AKI (HA-AKI). The pooled CA-AKI incidence was 8.3% 
and the incidence rate of HA-AKI was 12–31%, depending on hospital setting.42 Wonnacott 
et al. found opposite relations between community acquired and hospital acquired AKI. The 
incidence of HA-AKI was 2.1% and the incidence of CA-AKI was 4.3%, with an over-all 
incidence of 6.4%.50 The patients with HA-AKI was marginally older than those with CA-
AKI but despite that they carried the similar demographic and risk factors, but patients with 
CA-AKI had better short- and long-term outcomes.50 
The most common causes of HA-AKI—sepsis, cardiac surgery and exposure to radio-
contrast material—will be further described. 
	  
Sepsis	  
Sepsis is the most common cause of AKI; 45–70% of all AKI is shown to be associated with 
sepsis.13, 46 In the ICU, >50% of all cases of AKI are caused by sepsis.51 Among patients in a 
multicenter study >64% of patients with septic shock developed AKI within 24 hours of ICU 
admission. Patients with delay in receiving antibiotics had higher risk of developing AKI, and 
patients with AKI had increased mortality risk in the ICU (Odds Ratio (OR): 1.73; 95% 
confidence interval (CI): 1.6–1.9) and hospital (OR: 1.62; 95% CI: 1.5-1.7).52 Mehta et al. 







Formerly, AKI in sepsis was thought to be caused by changes in renal circulation leading to 
renal ischemia, cellular damage and acute tubular necrosis.54 Now, several studies suggest 
that AKI can develop in the absence of hypoperfusion, and might be caused by alterations in 
intra-renal circulation leading to endothelial dysfunction, inflammation, and coagulopathy.55-
59 Murugan et al. showed that most patients with sepsis are not admitted to the ICU, and do 
not express hemodynamic instability, despite this is AKI common.60 
 
Cardiac	  surgery	  
In 1998 Chertow et al. showed that ARF was independently associated with early mortality 
following cardiac surgery.11 As CABG has become a generally accepted and safe treatment 
for CAD, patients who undergo CABG have become older and affected by more co-
morbidities.8 As patients with less severe CAD are increasingly treated with PCI, the 
percentage of CABG-treated patients who have advanced CAD has also increased.8  
Cardiac surgery is the second most common cause of AKI; the incidence of cardiac surgery-
associated AKI is 8.9–39%61, 62 In cardiac surgery CABG is the procedure associate with the 
lowest risk for AKI, whereas combined procedures such as valvular replacement and 
concurrent CABG are associated with highest risk.45 Some risk factors for AKI are patient 
related, female sex, and comorbidities such as chronic obstructive pulmonary disease, 
diabetes mellitus (DM), low ejection fraction (EF), congestive heart failure, peripheral 
vascular disease, and CKD. Some other factors are procedure-related such as length of 
cardiopulmonary bypass (CPB),61, 63 use of an intra-aortic balloon pump, on pump more than 
off-pump surgery, non-pulsatile flow, decreased renal perfusion, hemolysis with release of 
free iron, inflammation, oxygen free radicals, oxidative stress and hemodilution.64, 65 The 
need for emergent surgery is also an important predictor for AKI.64 
Moreover, patients who undergo CABG, may have increased risk for AKI due to contrast 
exposure during coronary angiographies that has been performed just before surgery.  
 
Contrast-­‐induced	  acute	  kidney	  injury	  
Contrast-induced AKI (CI-AKI) after coronary angiography is the third leading cause of AKI 
among hospitalized patients,9, 66 with reported incidence of 2.6–13%.67, 68 An eGFR of less 
than 60 mL/min/1.73m2 is the most important risk marker for CI-AKI.69 Patients with 





hypotension, intra-aortic balloon pumps, heart failure, DM, and age older than 75 years are 
also at high risk.70 A consensus group stated that the risk for CI-AKI is clinically important 
when baseline SCr is >1.3 mg/dL (>115 µmol/L) for men and >1.0 mg/dL (88.4 µmol/L) for 
woman, which corresponds to an eGFR <60mL/min/1.73m2.69 Another study found that the 
incidence of AKI only became significant when iodinated contrast material was given to 
patients with a baseline SCr >1.8 mg/dL (>159 µmol/L).71 
 In AKI after coronary angiography, even small increases of SCr are associated with adverse 
outcomes but the mechanism is under debate. James et al. wrote a thorough review on the 
subject in which they concluded that CI-AKI is associated with increased risk of mortality, 
cardiovascular events and prolonged hospitalization, but the association is strongly 
confounded by several baseline characteristics of patients which are predictors for increased 
risks of both mortality and AKI.66 The risk for death after CI-AKI is overestimated in several 
studies, because adjustments for confounders were not performed.66 
In a recent study on >20 000 patients undergoing abdominal, thoracic or pelvic computer 
tomography the authors showed no difference in AKI-incidence, dialysis or 30-day mortality 
between patients receiving intravenous low-osmolar or iso-osmolar contrast material 
compared to those not receiving any contrast material.72 
 
PATHOPHYSIOLOGY	  OF	  ACUTE	  KIDNEY	  INJURY	  
The pathophysiology of AKI is a complex, multifactorial process with several different 
mechanisms. Historically, it has been divided into three categories: (1) The prerenal cause of 
AKI is reversible reduction of glomerular filtration rate due to decreased renal perfusion; for 
example due to hypovolemia, decreased cardiac output or severe vasoconstriction.73 (2) Renal 
causes of AKI include classical kidney diseases such as glomerulonephritis and nephrotoxic 
drugs such as contrast material, some antibiotics, diuretics, non-steroidal anti-inflammatory 
drugs (NSAIDs) and angiotensin converting enzyme (ACE) inhibitors.74, 75 Although studies 
on the use of ACE inhibitors before cardiac surgery present both reduction in AKI76 and is 
associated with increased AKI risk,77 whether ACE inhibitors cause AKI or exacerbate AKI 
by vasodilatation of efferent arterioles leading to decreased GFR is unclear.78 (3) Postrenal 
causes of AKI include conditions that cause mechanical obstruction of urinary flow, such as 
benign prostate hypertrophy, tumors and kidney stones. If these obstructions persist, 






A contemporary way of classifying AKI mechanism considers vascular, tubular, and 
inflammatory pathways, which are the same if the injury is caused by ischemia/reperfusion, 
toxins or sepsis.79 An injury that starts with trauma, for example, may cause a reduction in 
perfusion. This leads to depleted cellular adenosine triphosphate (ATP) and oxidative stress 
with release of cytokines and chemokines that recruit inflammatory cells. The inflammatory 
cells release more cytokines that worsen the epithelial injury. This causes loss of proximal 
tubular cytoskeletal polarity and integrity, which leads to a mislocalization of important 
membrane proteins such as Na/K-ATPases, detachment of tubular brush border cells from the 
basement membrane, apoptosis and necrosis.80 If the injury is severe enough, cellular debris 
is shredded out in the tubular lumen and parts of the basement membrane are left exposed as 
the sole barrier between the filtrate and the peritubular interstitium. These naked areas, 
combined with increased pressure in the tubules (due to cellular debris causing obstruction) 
can cause back leak of fluid and interstitial edema.79 Instantly, in response to the injury, 
viable epithelial cells start the repair process. In a favorable milieu with nutrients and oxygen, 
migration and division of epithelial cells (re-differentiation) restores and heal the brush 
border, and cellular polarity and integrity recover.81 However, in prolonged ischemia, the 
inflammatory response exacerbates the injury due to release of inflammatory mediators and 
vasoconstrictors.79 Whether other pathways of tubular injury exist—for example severe 
ischemia that leads to transformation of epithelial cells into fibroblasts, thus promoting 
fibrosis and chronic kidney disease—is a point of debate. Other studies suggest that the 
kidney heals with development of fibrosis, which could explain why AKI seems to accelerate 
progression of CKD.79, 82 
 
PATHOPHYSIOLOGY	  OF	  CARDIAC	  SURGERY	  ASSOCIATED	  ACUTE	  KIDNEY	  INJURY	  
In a review article by Bellomo et al. the pathophysiology of cardiac surgery associated AKI is 
explained in six different mechanisms and/or pathways; Exogenous and endogenous toxins, 
metabolic factors, ischemia-reperfusion, neurohormonal activation, inflammation and 
oxidative stress.65 The authors point out that causation cannot be established, and to perform 
a RCT to evaluate the effect of a single factor is difficult since the different pathways and 
factors act synergistically.  
Exogenous toxins, for example some antibiotics, contrast material, ACE inhibitors and 
NSAIDs could harm the kidneys in some patients. Hemolysis during CPB causes release of 





free hemoglobin and iron, which can act as endogenous toxins. Also rhabdomyolysis can 
occur, which in turn can act as an endogenous toxin.65 
Metabolic factors including DM are independently associated with AKI and DM is common 
among patients having CABG.65, 83, 84 Extremes of body mass index are also associated with 
AKI.65 
Ischemia can be caused by a variety of disorders; hemodynamic instability with low cardiac 
output, hypovolemia, overdose of vasodilator, or renal artery embolism originated from for 
example the time of cardiac catheterization and cannulation. Air embolism can also cause 
ischemia.65 
During anesthesia and CPB mean arterial pressure is often in the lower range of the kidneys 
autoregulatory limit of 80 mmHg.83 Long duration of CPB, low flow and longer periods with 
mean arterial pressure less than 60 mmHg have been associated with AKI.85 When CPB is 
discontinued the remaining heparin in the circulation is reversed with protamine that causes 
vasodilatation and hypotension leading to a low cardiac output. A low intravascular volume 
may also lead to impaired renal perfusion.65 A balanced use of vasopressors and volume 
infusion is vital for the kidney perfusion.  
There are several neurohormonal responses to CPB that are affected by cross-clamp time and 
duration of CPB. For example plasma levels of norepinephrine, epinephrine, vasopressin and 
dopamine are elevated during CPB. This leads to a reduction in renal blood flow and a 
reduction of GFR.65 Use of CPB is associated with a systemic inflammatory response during 
and after cardiac surgery.86 Some studies have used sodium bicarbonate in a nephro 
preventive action for oxidative stress postoperatively, however without effect.65, 87 
 
PREVENTION	  AND	  TREATMENT	  OF	  ACUTE	  KIDNEY	  INJURY	  	  
Maintaining balanced volume status is important in preventing and treating AKI. The goal is 
to keep a mean arterial pressure and to restore cardiac output to reach an adequate renal 
perfusion pressure and oxygen delivery. Hypovolemia is known to be a risk factor for AKI. 
However, some studies have associated fluid overload with adverse outcomes such as 
increased 60-day mortality, prolonged ventilator use among patients with acute lung injury, 
and worse cardiac function after cardiac surgery.88-91 In a review article, Prowle et al. 






cause high central venous pressure and congestion in the kidney and lead to decreased GFR. 
Fluid overload is associated with adverse outcomes and can contribute to persistent AKI.92 
Prowle et al. suggest a thorough assessment of fluid status during volume resuscitation.92 The 
KDIGO work group suggest isotonic crystalloids at initial management for volume 
optimization in patients at risk for, or with established AKI.33 The use of vasopressors 
combined with fluids is also recommended.33 
Several studies have investigated the effect of inflammation induced by CPB.93, 94 
Hypothetically, remote ischemic preconditioning can mitigate inflammation, but study results 
vary. Some studies show remote ischemic preconditioning to have no effect during cardiac 
surgery.94-96 A randomized controlled trial (RCT) that investigated remote ischemic 
preconditioning in patients who underwent CABG showed the incidence of AKI to be 
reduced by 48%.97 A smaller RCT showed reduced risk of AKI among patients who 
underwent ischemic preconditioning.98 
Sodium bicarbonate reportedly reduces the incidence AKI after cardiac surgery, but a 
systematic review by Tie et al. found no benefits in using sodium bicarbonate to prevent 
AKI.99 Instead, it prolonged mechanical ventilation and ICU stays, and increased risk for 
alkalemia.99 Haase et al. showed no reduction in incidence of AKI and increased mortality 
among patients who underwent cardiac surgery and received sodium bicarbonate; this study 




Kidneys play important roles in several vital anatomical systems. Every minute, 20% of the 
cardiac output passes through the kidneys.73 The main function of the kidneys is to clean the 
blood of water-soluble waste products from our metabolism and excretion of some foreign 
toxins and medications. Through production of urine, kidneys regulate the balance of fluids 
and electrolytes within the body, acid-base balance, and blood pressure. Kidneys also produce 
several important hormones such as erythropoietin, which is vital for production of red blood 
cells and vitamin D.73 The kidney has a special blood supply to the renal medulla; the 
medulla functions well at low oxygen tension, but, is very sensitive to changes in blood flow. 
 





Glomerular	  filtration	  rate	  
The definition of GFR is volume of plasma filtered by the kidneys per minute.73 The normal 
GFR range is 90–130 mL/min/1.73m2.100 Starting around the fifth decade of life, GFR 
decreases by about 10 mL/min/1.73m2 each decade.  
GFR can be determined by using an exogenous substance that is freely filtered by the 
kidneys. Inulin clearance is considered gold standard for measurement of kidney function but 
this method is complicated, time-consuming and expensive.101  
Serum creatinine is affected by several factors, such as muscle mass, liver disease, 
inflammation and muscle wasting, which limit the accuracy of creatinine testing.102 To 
overcome these limitations, several formulas have been developed to increase the precision of 
estimates by incorporating age, ethnicity, sex, body size and serum creatinine concentration 
as variables. Most GFR estimation formulas work quite well in patients with GFR < 60 but 
are less precise in patients with high GFRs.  
 
Formulas for estimation of glomerular filtration rate 
Three main formulas are used to estimate GFR. The Cockcroft–Gault formula was developed 
in 1973. This formula does not take body size into account and tends to overestimate GFR in 
obese patients and underestimate GFR in elderly patients.103 The Cockcroft–Gault formula 
has been validated in several studies and is considered to be accurate for patients younger 
than 65 years with eGFRs between 20–60 mL/min/1.73m2. 
The Modification of Diet in Renal Disease (MDRD) Study Equation was developed in 1999. 
It has been simplified to four variables (age, ethnicity, sex, serum creatinine).25 MDRD is 
more precise than the Cockcroft–Gault formula but it underestimates GFR among patients 
with GFR >60 mL/min/1.73m2. 
The Chronic Kidney Disease-Epidemiology Collaboration formula was developed in 2009. It 
uses the same parameters as the MDRD formula. It functions as well as MDRD among 








CHRONIC	  KIDNEY	  DISEASE	  
Chronic kidney disease is a general term for a variety of conditions that affect the kidney. In 
2002, the National Kidney Foundation´s Kidney Disease Outcome Quality Initiative 
presented guidelines for classification and evaluation of CKD.23 The definition of CKD is 
based on the presence of kidney damage (albuminuria) or decreased kidney function (GFR 
<60 mL/min/1.73m2) that persists for over 3 months. CKD is divided into five stages, 
depending on GFR value (Table 3).23 
 
Table 3. Stages of chronic kidney disease 
Stage GFR Description 
1 ≥90 Kidney damage (albuminuria) with normal GFR 
2 60–89 Kidney damage (albuminuria) with mild decrease of GFR 
3 a 45–59 Moderate reduction of GFR. In the US this is merged to one group with GFR 30–59. In Europe it is divided into two subgroups; 3a and 3b. 
3 b 30–45  
4 15–29 Severe reduction of GFR 
5 <15 Kidney failure. 
GFR, Glomerular filtration rate, mL/min/1.73m2. 
 
Several epidemiological studies have shown that patients with CKD are at a higher risk for 
death, development of cardiovascular disease, congestive heart failure and symptomatic 
peripheral vascular disease.105-108 Severity of albuminuria and adverse outcomes like 
mortality in different populations have been related, even after adjustment for confounders 
such as low GFR and other risk factors for cardiovascular disease.109, 110  
	  
SERUM	  MARKERS	  OF	  RENAL	  FUNCTION	  	  
Creatinine 
Creatine is synthesized in the liver from methionine, glycine and arginine but a small amount 
is also ingested through our diet, mainly meat. In skeletal muscle creatine is phosphorylated 
to form phosphorylcreatine, which is an important energy store for ATP synthesis. Muscle 
contains 98% of the total amount of creatinine in the body.100 Creatinine is a 113 Da amino 





acid product from the breakdown of phosphorylcreatine in muscle. Creatinine is distributed 
throughout the total body water and is freely excreted by the kidneys, primarily by glomerular 
filtration.100 An estimated 10–40% of creatinine clearance is also actively secreted by tubular 
cells in the kidney and by extra renal secretion.111 Because of this, creatinine clearance 
normally exceeds GFR.102  
 
Cystatin C 
Cystatin C is a 13 kDa basic protein that is produced at a constant rate by all nucleated cells. 
Cystatin C is freely filtered by the glomerulus and metabolized by the tubular epithelial 
cells.112 As no tubular secretion and only minimal extra-renal excretion occur, serum 
concentration of Cystatin C depends mainly on GFR.113 Generation of Cystatin C seems to be 
less affected by age, sex and muscle mass than that of creatinine. However, corticosteroid 
use, high levels of C-reactive protein and hypo/hyperthyroidism affect the level of Cystatin 
C.114, 115 
 
BIOMARKERS	  FOR	  KIDNEY	  INJURY	  
The AKI definition is based on changes in levels of SCr, which is a surrogate marker for 
kidney injury. As SCr levels take several hours to begin to increase, and as much as 48 hours 
to peak after an injury to the kidney has occurred, an injury may be detected too late to 
prevent the injury from becoming permanent. A more sensitive biomarker that could detect 
kidney injury at an earlier stage would allow preventive actions to be taken. An ideal 
biomarker would be precise, reliable and highly sensitive for early-stage AKI. In addition, it 
would indicate the etiology of AKI (caused by, for example, sepsis, nephrotoxins, cardiac 
surgery, or contrast material). Ideally, it would also be inexpensive, easy to use and possible 
to standardize for clinical use,116 and would indicate severity, and help monitor recovery, of 
AKI. Of several biomarkers at experimental stages, none fulfill all these criteria; however, a 







Kidney injury molecule -1 
Kidney injury molecule-1 (KIM-1) is a transmembrane glycoprotein that is normally 
expressed in kidney tissue in small amounts. KIM-1 seems to be produced by proximal 
tubular cells in cases of kidney ischemia or if the kidney is affected by nephrotoxins.117 KIM-
1 transforms tubular epithelial cells into phagocytes that clear the lumen of cellular debris 
thereby aiding the process of regeneration and healing, and limiting the autoimmune response 
to apoptosis.117-119 KIM-1 levels can be detected in urine, and increase when tubuli are 
injured. KIM-1 has been shown to be a sensitive biomarker for AKI after cardiac surgery120 
and is independently associated with long-term mortality.121 In a recent investigation of the 
predictive abilities of 32 different biomarkers, alone or in combination, Arthur et al. found 
KIM-1 to be a good predictor for higher AKIN stage or death (area under the curve (AUC) 
0.73), or for AKIN stage 3 or death (AUC: 0.81), but had a relatively weak correlation with 
the other markers studied.122 
 
Neutrophil gelatinase-associated lipocalin  
Human neutrophil gelatinase-assocated lipocalin (NGAL) is a 25 kDa protein that is bound to 
gelatinase from neutrophils. NGAL is normally expressed at very low levels in kidneys, but 
its production in tubular cells increases markedly after renal injury.123 Wagener et al. found 
urinary NGAL to rise significantly in the early postoperative period among patients who 
developed AKI after cardiac surgery.124 In another study NGAL predicted progression of 
kidney injury or death after cardiac surgery relatively well (AUC: 0.72).122 
 
Interleukin-18 
Interleukin 18 (IL-18) is an 18 kDa cytokine secreted by proximal tubular cells and 
leucocytes when tubular cells are injured.125 In an animal model, inhibition of IL-18 protected 
against ischemic kidney injury, which support its significance in development of AKI.125 
Parikh et al. showed that IL-18 levels peak within 6 hours of cardiac surgery and were 
associated with development of AKI in the postoperative period.126 In the aforementioned 
study of patients who underwent cardiac surgery, Arthur et al. showed IL-18 to be the best 
single predictor of the outcomes under study of the 32 tested biomarkers, and to have the 
highest predictive ability when combined with KIM-1.122 






FUROSEMIDE	  STRESS	  TEST	  
An established means of assessing kidney function among patients with oliguria is the use of 
furosemide. In a study of Baek et al. in 1973,127 patients were each given a bolus of 
furosemide and free water clearance was evaluated. The authors concluded that acute renal 
failure was forthcoming in patients who did not respond to the furosemide bolus.127 Even 
though this “furosemide test” is commonly performed at hospitals worldwide, it has no 
protocol or standardized execution, and had not been validated. In 2013, Chawla and 
colleagues showed that a single dose of 1.0 or 1.5 mg/kg of furosemide predicted if patients 
with early AKI would progress to AKIN stage III (AUC: 0.82–0.87),128 which implies that, as 
a predictor of AKI, the furosemide stress test is as good or better than use of newer marker 
such as IL-18.122 The furosemide stress test is also inexpensive, easy to perform and readily 
available.  
 
CORONARY	  ARTERY	  BYPASS	  GRAFTING	  	  
Coronary artery bypass and cardiac surgery are suitable for studying AKI, for two reasons. 
First, AKI is common after CABG, affecting 10−20% of patients in different cohorts; second, 
and most importantly, the timing of the injury is known, which is not true for patients with 
sepsis, for example.  
The first successful open heart operation using CPB to close an atrial septal defect was 
performed in May 1953 by John Gibbon in Boston.129 The second successful open heart 
operation in the world was done by Clarence Crafoord who removed an atrial myxoma in 
July 1954 at the Sabbatsberg Hospital in Stockholm.130 Subsequent improvements in cardio-
pulmonary bypass, surgical techniques, anesthesia and perioperative management opened up 
possibilities to perform extensive cardiac surgery. The first successful human CABG was 
performed in the United States 1960 by Dr. Goetz and Dr. Rothman.131 Clinical introduction 
of CABG started after pioneering work at the Cleveland Clinics in 1967.132 CABG evolved 
over the following decades to become a common surgical procedure. In 2012, 6009 open-
heart procedures were performed in Sweden, of which 2736 were CABG (46%). In 






90s. The number of cardiac surgeries performed worldwide has decreased during the last 
decade after the advent of PCI.133  
Over the last decade, patients undergoing CABG have become older, with more 
comorbidities.8 Patients with less severe CAD are more likely to be suitable for PCI, leaving 
patients with a more advanced CAD to surgery.134 Several studies have shown that patients 
with two or more diseased coronary arteries have better long-term survival and a smaller risk 
of revascularization de novo when having CABG compared with PCI, including the use of 
drug-eluting stents.134-139 Another study showed lower mortality rates in the CABG group 
than the PCI group.136 In the FREEDOM (Future Revascularization Evaluation in patients 
with Diabetes Mellitus: Optimal Management of Multivessel Disease) trial death or MI 
occurred more often after PCI than CABG in diabetic patients followed for five years.140  
For prediction of perioperative mortality The European System for Cardiac Operative Risk 
Evaluation Score (EuroSCORE) was developed as a risk-scoring system for patients 
undergoing CABG.141 It provides a simple additive risk model that consists of 18 variables 
divided into three groups; patient related, cardiac related and operation-related factors with 
different scores ranging from 1–4. The EuroSCORE 0-2 is considered low risk, 3-5 medium 
risk, and >6 high risk.141 EuroSCORE is validated in several studies.7, 142-144  






AIMS	  OF	  THE	  THESIS	  
 
The overall aim of this thesis was to investigate the effect of AKI on short- and long-term 
outcomes after CABG. Our specific aims were: 
• To study the association between AKI and short-term mortality and postoperative 
complications in patients who underwent CABG. 
 
• To study the association between AKI and long-term mortality and risk for 
myocardial infarction and death in patients who underwent CABG.  
 
• To study the association between AKI and the risk of stroke in patients who 
underwent CABG. 
 
• To study the association between AKI and long-term risk of development of end-
stage renal disease in patients who underwent CABG. 






SUBJECTS	  AND	  METHODS	  
 
Table 4 present an overview of study design and outcome measures in the thesis. 
Table 4. Summary of subjects and methods in the thesis. 
 Study I Study II Study III Study IV 








Study population Patients who 
underwent a first 




underwent a first 




underwent a first 




underwent a first 
isolated CABG in 
Sweden from 
SWEDEHEART 
Number of subjects 7594 27 929 23 584 29 330 
Study period February 1995 to 
December 2006 
January 2000 to 
December 2008 
January 2000 to 
December 2008 
January 2000 to 
December 2008 


















term mortality  
Long-term risk for 
stroke  
ESRD and long-
term mortality  
CABG, Coronary Artery Bypass Grafting; ESRD, End-stage renal disease; SWEDEHEART, Swedish Web-





The Swedish Web-System for Enhancement and Development of Evidence-based care in 
Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) is a 
national Swedish register with the aim of supporting evidence-based development of 
therapies in acute and chronic coronary artery disease and in catheter-based or surgical valve 
intervention. Additionally, the SWEDEHEART register aims to improve care for patients 






between each other, and to provide a basis for research.145 National, regional and county-
based reports are presented every year.133 All clinics that treat patients with coronary artery 
disease report to SWEDEHEART on a yearly basis. The register consists of five parts; RIKS-
HIA, the register on myocardial infarction care; SEPHIA, the register for secondary 
prevention following coronary intensive care; SCAAR, the register for coronary angiography 
and PCI; the Percutaneous Valve register; and The Swedish Heart Surgery Register. Baseline 
patient characteristics are collected at admission to hospital. 
The Swedish Heart Surgery Register, where all adult heart surgery performed in Sweden is 
reported, was started in 1992. Heart surgery is currently performed at eight hospitals in 
Sweden.  
The validation process of data in SWEDEHEART includes a visit by a monitor in 
approximately 20 random hospitals every year and compares information from medical 
records of 30–40 randomly chosen patients to the information in the register. Agreement 
between the information in the register and medical records is about 93–97%.146 The validity 
of the information on postoperative complications is less reliable, as it depends on the 
thoroughness of the physician who does the registration.133 The coverage of SWEDEHEART 
is 100% for patients undergoing cardiac surgery, angiography and PCI, and almost 100% for 
patients with acute coronary syndrome admitted to a coronary care unit—about 60% of all 
acute coronary syndrome cases.146  
 
The	  Swedish	  National	  Patient	  Register	  
The Swedish National Board of Health and Welfare started the National Patient Register 
(NPR) in 1964. Since 1987, it has covered the whole country.147 The National Patient 
Register contains information on each patient’s personal identity number, age, sex, place of 
residence, county, hospital/clinic, department, dates of admission and discharge, lengths of 
hospital stays, acute/planned admissions, admitted-from and discharged-to data, primary 
diagnoses, secondary diagnoses, external causes of injury or poisoning and procedures. All 
county councils in Sweden report this information yearly.147 Discharge codes are classified 
according to the International Classifications of Diseases (ICD). Some variables are missing 
in NPR; in 2006, 0.6% of records were missing personal identity numbers and 1% were 
missing principal diagnoses.147 In the NPR, MI148 and stroke149 as principal cause of 
hospitalization has a positive predictive value of 98%. 





The	  Cause	  Of	  Death	  Register	  
The Cause of Death Register was started in 1952 and is under the supervision of the Swedish 
National Board of Health and Welfare.150 The Swedish Cause of Death Register contains all 
deceased people in Sweden since 1961. Information on date of death and contributing causes 
are also registered. About 1–2% of their records have a missing cause of death. The missing 
cases are coded without known cause of death.150  
	  
The	  Swedish	  Renal	  Registry	  
The Swedish Renal Registry was founded in 2007 when several local registries in Sweden; 
the Swedish Register for Active Treatment of Uremia (1991) and the Swedish Dialysis 
Database merged to form a nationwide register.151 All nephrology and transplantation units in 
Sweden report to this register through a webpage. It functions as a quality register for patients 
with ESRD under the supervision of the Swedish Society of Nephrology and the Swedish 
Transplantation Society.151 Patients enter this register when they start their first active 
treatment for ESRD, or receive kidney transplants.  Discontinuation of treatment leads to 
removal from the register. 
	  
Total	  Population	  Register	  
The total population register is a part of Statistics Sweden. It includes such data as name, 
place of birth and residence, sex, age, civil status, citizenship, immigration and relationships 
such as married couples and child–parent.6 The total population register is updated 
continuously. An estimated 93% of all death are reported to Statistics Sweden within 10 days 
and 100% within one month.6 
	  
The	  Swedish	  Personal	  Identification	  Number	  
Since 1947, all citizens in Sweden carry a unique personal identity number. It consists of ten 
digits: the year and date of birth and a four-digit control number.152 This personal identity 
number covers virtually the whole Swedish healthcare system and facilitates linkage between 
different registers in epidemiological studies.152 When an individual stays in Sweden on a 
permanent basis and is recorded in the Total population register, they are given a personal 







STUDY	  POPULATION	  AND	  DATA	  COLLECTION	  
Study	  I	  
This cohort was retrieved from a local database at Karolinska Hospital, and consisted of all 
8298 patients who underwent a first isolated CABG between February 1995 and December 
2006, excluding 704 patients because of missing information on pre-and/or postoperative 
SCr, leaving 7594 patients for final analysis. Several variables were collected prospectively 
from medical records: age, sex, weight, height, DM, peripheral vascular disease, left 
ventricular function (LVF), prior stroke or MI, acute coronary syndrome, pre- and 
postoperative SCr, dialysis dependent renal failure number of significantly obstructed 
coronary arteries, and date of surgery. 
 
Studies	  II-­‐IV	  
The Studies II-IV cohorts were retrieved from the SWEDEHEART register and consisted of 
50 244 patients who underwent CABG between 2000 and 2008 in Sweden. Exclusion criteria 
in study II–IV are presented in Figure 1.  
 
Figure 1. Exclusion criteria in study II, III, and IV. 
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Information on the following clinical characteristics were collected from SWEDEHEART: 
age, sex, current smoking, preoperative eGFR, preoperative SCr, DM, hypertension, 
hyperlipidemia, peripheral vascular disease, chronic obstructive pulmonary disease, LVF, 
EuroSCORE, use of internal thoracic artery, off-pump surgery, and length of hospital stay. 
Information on prior hospitalization for chronic obstructive pulmonary disease, congestive 
heart failure, prior MI, and prior stroke was obtained from the NPR. Information on prior 
renal replacement therapy was collected from SWEDEHEART. 
	  
Laboratory	  method	  and	  other	  variables	  
Serum creatinine 
In all studies, GFR was estimated using the abbreviated MDRD formula25 as follows;  
eGFR = 186.3 × (SCr in µmol per L / 88.4)−1.154 × age−0.203 (× 0.742 if female) 
 
Study I 
Baseline SCr was measured at the time of admission to the ward, normally the day before 
surgery or within one week prior to surgery. Among 483 patients with AKI, we scrutinized 
all SCr values through medical records, during the entire hospitalization, and found that in 
93% of patients the 48-hour SCr value corresponded to the highest postoperative value.  
All serum creatinine samples were analyzed at the same laboratory at the Karolinska 
University Hospital Stockholm, Sweden. There was a change of analysis method in March 
2005 from the nonkinetic alkaline Jaffé method to an enzymatic method with somewhat 




Baseline SCr was measured at the time of admission to the ward, normally the day before 
surgery or within one week prior to surgery. The serum creatinine samples were analyzed at 







Classification	  of	  acute	  kidney	  injury	  
Study I and IV 
Acute kidney injury was classified according to the AKIN classification—stage 1: increase 
by SCr ≥26 µmol/L (≥0.3 mg/dL) or an increase by 50−100% of baseline SCr; stage 2: 
increase by 100−200% of baseline value; and stage 3: >200% increase of baseline SCr. In a 
complementary analysis for Study I, we also defined patients by the RIFLE stage 1 criteria: 
increase by 50−100% of baseline SCr. 
 
Studies II and III 
Acute kidney injury was classified according to AKIN and another classification based on 
absolute increases of SCr. The division in absolute increases in SCr was based on the AKIN 
criteria and divided into three stages of AKI—stage 1: SCr increase of 26–44 µmol/L 
(0.3−0.5 mg/dL), stage 2: SCr increase of 44-88 µmol/L (0.5−1.0 mg/dL) and stage 3: SCr 
increase of ≥88 µmol/L (≥1.0 mg/dL) compared with the preoperative baseline SCr value. 
 
Definition	  of	  co-­‐morbidities	  
Information on co-morbidities was collected from SWEDEHEART and NPR. Patients were 
defined as having hypertension if they were taking antihypertensive medication and defined 
as having DM if they had ongoing treatment with insulin or oral hypoglycemic agents. 
Peripheral vascular disease was defined as one or more of the following: claudication, 
carotid occlusion or >50% stenosis, amputation for arterial disease or previous or planned 
intervention on the abdominal aorta, limb arteries or carotids. Left ventricular function was 
measured by preoperative echocardiography or ventriculography. Ejection fraction (EF) was 
considered normal if >55%, reduced if EF was 30–55%, and severely reduced if <30%. 
Chronic kidney disease was defined as GFR <60 mL/min/1.73m2 calculated by the MDRD 
equation. Stroke and MI were defined according to ICD codes from NPR.  
 






Outcomes in Study I: short-term (i.e. 60 days) risk for all-cause mortality and postoperative 
stroke and mediastinitis; in Study II: long-term risk of all-cause mortality and MI; in Study 
III; long-term risk of stroke; and Study IV: long-term risk of ESRD or ESRD and death.  
 
Follow-up 
In Study I, follow-up started when SCr was analyzed postoperatively to classify AKI. In 93% 
of samples, this occurred within 48 hours after surgery. Follow-up ended 60 days after 
surgery. Information on deceased patients was retrieved by linking the patients personal 
identity number to the Cause of Death register. Stroke was defined as central neurological 
symptoms persisting >72 hours. Mediastinitis was defined as a deep sternal wound infection 
requiring antibiotics and surgical intervention. 
All-cause mortality was an outcome in all four studies. In Studies II−IV, information on 
deceased patients was obtained from the total population register. 
In Study II, follow-up started at the date of surgery and ended when patients were discharged 
with a principal discharge diagnosis of MI defined by code I21 in ICD 10 (received from 
NPR), died, or until 31 December 2009, whichever occurred first.  
In Study III, follow-up started 30 days after surgery and patients were followed until they 
were discharged with a principal diagnosis of any stroke (ICD I63.9, I61.9), died, or until 31 
December 2008, whichever occurred first. Information on stroke vas obtained from NPR, 
where stroke has a positive predictive value of 98.6%.149 
In Study IV, follow-up started 30 days after surgery and patients were followed until the date 
when they first appeared in the renal register, died, or until 31 December 2008, whichever 









Baseline characteristics among the patients were presented with one standard deviation (SD) 
and percentages in the different AKIN stages and then compared between groups by 
calculating P–values using Mantel–Haentzels test. Logistic regression analysis was 
performed crude and after adjustment for potential confounders from patient characteristics to 
calculate odds ratios (OR) for mortality within 60 days of surgery among patients in AKIN 
stages 1 and stages 2–3 combined, compared with patients without AKI. The OR was 
presented with 95% CI. In the multivariable adjusted model, confounders that affected the 
OR >0.1 were included in the final model. 
We also examined the ability of AKIN and RIFLE to identify early deaths by using ROC. 
AUCs were calculated and compared by nonparametric methods by Mann−Whitney and χ2 
tests. SAS statistical software, version 9.2 (SAS Institute, Inc. Cary, NC) was used for all 
statistical analyses. 
 
Studies	  II	  -­‐	  IV	  
Continuous baseline variables were presented using means and one SD. Categorical variables 
show percentages in relation to AKI group. Some values were missing from datasets in 
Studies II-IV, including left ventricular ejection fraction (in 7.7% of patients), information on 
diabetes mellitus (in 26%), and peripheral vascular disease (in 7.4%). Imputation by chained 
equations was used to handle missing baseline values for LVF and DM in Study II, DM and 
peripheral vascular disease in Study III and LVF, DM and peripheral vascular disease in 
study IV, thereby permitting multivariable adjustment for confounders in the whole cohort. 
The Kaplan–Meier method was used to calculate cumulative incidences of outcomes in 
relation to different AKI groups. Univariate and multivariable Cox regression analysis was 
used to handle confounding factors and calculate HR with 95% CI for outcomes among 
patients with AKI compared with patient without AKI. In Studies III and IV, we used 
competing risk regression analysis to handle death as a competing risk.  
Stata version12.1 (StataCorp LP, College Station, TX, USA) was used for all analyses in 
Studies II and III; version 13.1 was used in study IV. 







STUDY	  I	  	  
Patient characteristics 
Baseline characteristics of all patients in Study I are shown in Table 5. Over all, the incidence 
of AKI was 14%. Generally, patients with AKI were older, more likely to be female and 
suffered from more co-morbidities than did patients without AKI. 
 
Table 5. Preoperative characteristics of patients in Study I classified by Acute Kidney Injury Network (AKIN) 
classification stage*. 
 All patients No AKI AKIN 1 AKIN 2 AKIN 3 
All patients (%) 7594 (100) 6547 (86.2) 918 (12.1) 108 (1.4) 21 (0.3) 
Women (%) 1549 (20) 1350 (21) 174 (19) 19 (18) 6 (29) 
Diabetes mellitus (%) 1536 (20) 1262 (19) 247 (27) 24 (23) 3 (14) 
Preoperative eGFR 
<60 mL/min/1.73m2 (%) 1361 (18) 979 (15) 358 (39) 21 (19) 3 (14) 
LVF -Normal (%) 4675 (62) 4157 (63) 461 (50) 46 (43) 11 (52) 
 -Decreased (%) 2137 (28) 1762 (27) 322 (35) 45 (42) 8 (38) 
 -Severely Decreased (%) 460 (6.1) 362 (5.5) 83 (9.0) 13 (12) 2 (9.5) 
Unstable angina pectoris (%) 3444 (45) 2908 (44) 465 (51) 58 (54) 13 (62) 
Age, mean (SD), years 65.5 (9.7) 65.2 (9.7) 68.5 (9.8) 67.1 (9.6) 68.2 (9.0) 
Serum Creatinine, mean (μmol/L) 
(SD) 
92 (31) 91 (26) 114 (54) 92 (29) 83 (27) 
*AKIN, Stage 1: Increase in serum creatinine >0.3 mg/dL or a serum creatinine of 150–200% of baseline value. 
Stage 2: Serum creatinine of 200–300% of baseline value. Stage 3: Serum creatinine of >300% of baseline value. 
AKI, acute kidney injury; LVF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; SD, 




Of 7594 patients, 132 (1.7%) died during follow-up. The proportion of patients who died 
increased with increasing AKIN stage. The ORs for death within 60 days of surgery 
gradually increased, even after multivariable adjustment for several confounders. Compared 






in stages 2–3 had 20-times the risk (Table 6). In a subgroup analysis of 2984 patients, we 
calculated ORs for short-term mortality and found that the high mortality risk persisted even 
after adjustment for timing of coronary angiography was included in the statistical model; its 
inclusion did not significantly change the OR values. Furthermore, we stratified patients 
according to eGFR above and below 60 mL/min/1.73m2, and found similar results in both 
categories of renal function.  
Comparison between AKIN and RIFLE by ROC analysis showed a better prediction of death 
with AKIN (AUC: AKIN, 0.74; RIFLE, 0.66; P <0.01). 
	  
Postoperative complications  
Among patients without AKI, 1.0% developed a postoperative stroke and 1.1% mediastinitis. 
Among patients with AKI, 3.4% of those in AKIN stage 1 and 7.8% in AKIN stages 2+3 
developed strokes. A similar association was found between AKI and mediastinitis (Table 6). 
 
Table 6. Incidence of mortality, stroke, and mediastinitis within 60 days of coronary bypass grafting in 
relation to acute kidney injury classified by Acute Kidney Injury Network (AKIN) stage*. Odds ratios 
were calculated relative to patients without acute kidney injury and presented with 95% confidence 
intervals. 
  AKIN stage 
 All patients No AKI Stage 1  Stage 2 and 3  
Number of patients 7594 6547 918 129 
Mortality 132 (1.7%) 54 (0.82%) 54 (5.9%) 24 (19%) 
Multivariable adjustment†  1.0 4.36 (2.83-6.71) 21.5 (12.0-38.6) 
     
Number of patients 7568 6523 918 129 
Stroke 103 (1.4%) 62 (1.0%) 31 (3.4%) 10 (7.8%) 
Multivariable adjustment†  1.0 2.34 (1.43-3.82) 6.52 (2.97-14.3) 
     
Number of patients 7594 6547 918 129 
Mediastinitis 118 (1.6%) 74 (1.1%) 36 (3.9%) 8 (6.2%) 
Multivariable adjustment†  1.0 2.88 (1.84-4.50) 4.68 (2.07-10.6) 
*AKIN,  Stage 1: Increase in serum creatinine (SCr) >0.3 mg/dL or SCr of 150–200%. Stage 2: SCr of 200–
300%. Stage 3: SCr of >300%, all compared to baseline value. AKI, acute kidney injury; OR, odds ratio; CI, 
confidence interval. †Adjusted for; age, gender, preoperative estimated glomerular filtration rate, left ventricular 
function, diabetes mellitus, body mass index, unstable angina pectoris. 







Patient characteristics are presented in Table 7. Their mean age was 67 years and 21% were 
women. In total, 13 % of these patients developed AKI after surgery. The largest percentage, 
6.3% were in AKI stage 1, 4.3% in stage 2 and 2.3% in AKI stage 3. Of all 27 927 patients, 
20% had eGFRs <60 mL/min/1.73m2 before undergoing CABG. Patients with AKI had more 





Table	  7.	  Characteristics	  of	  the	  study	  population	  in	  relation	  to	  acute	  kidney	  injury,	  classified	  by	  
absolute	  increases	  in	  postoperative	  serum	  creatinine	  values*.	  
 All patients No AKI Stage 1 Stage 2 Stage 3 
Number of patients (%) 27 929 (100) 24 312 (87) 1763 (6.3) 1209 (4.3) 645 (2.3) 
Age, mean (SD), years 67.1 (9.2) 66.6 (9.2) 70.0 (8.8) 70.9 (8.8) 71.2 (9.0) 
Preoperative. eGFR 
mL/min/1.73m2%      
eGFR >60 80 82 69 58 44 
eGFR 45–60 15 14 21 24 24 
eGFR 30–45  4 3 8 14 19 
eGFR 15–30  1.0 0.5 2 4 13 
Female sex, n (%) 5967 (21) 5229 (22) 357 (20) 252 (21) 129 (20) 
Preoperative SCr (SD), mg/dL 1.0 (0.3) 1.0 (0.3) 1.1 (0.4) 1.2 (0.5) 1.5 (0.7) 
EuroSCORE (SD) 3.8 (2.5) 3.7 (2.4) 4.6 (2.5) 5.0 (2.5) 5.6 (2.6) 
Prior MI, % 42 40 46 51 55 
Prior hospitalization for CHF, % 4 3 6 9 10 
Left ventricular function, %      
Ejection fraction >50%  70 72 65 58 55 
Ejection fraction 30–50% 26 25 30 35 35 
Ejection fraction < 30% 4 4 5 6 9 
AKI, acute kidney injury; SD, standard deviation; eGFR, estimated glomerular filtration rate; SCr, serum 
creatinine; CABG, coronary artery bypass grafting; EuroSCORE,	  European	  system	  for	  cardiac	  operative	  risk	  evaluation; MI, myocardial infarction; CHF, congestive heart failure. Age, and SCr values are given as means 
with standard deviations. *Acute kidney injury classified according to absolute raise in SCr values. Stage 1: 0.3–








Myocardial infarction and death 
This population had 2119 (7.6%) myocardial infarctions and 4679 (17%) deaths over a mean 
follow-up period of 5.0 years, and showed increasing risk of MI with advancing AKI stage 
over time (Figure 2). Patients without AKI were more likely to be alive throughout the study 
period (Figure 3). 
 
Figure 2. Cumulative incidence of myocardial infarction in 27 929 patients who underwent primary 
isolated coronary artery bypass grafting in Sweden, 2000–2008. The inset shows the same data on a 
rescaled y-axis. 
 
Figure 3. Cumulative survival in 27 929 patients who underwent primary isolated coronary artery 
bypass grafting in Sweden, 2000–2008. 
 





The HR for MI is presented in Table 8. In an additional analysis, we excluded all patients 
who died (n=502) or had an MI (n=828) within 60 days of surgery and calculated HRs for 
death or MI during follow-up. After adjustment for confounders, the results were similar to 
the HRs for the cohort as a whole. 
In addition, we performed a complete case analysis of only patients with no missing 
covariates, and found results to be similar to the analysis with imputed missing covariates.	  	  	  
Table 8. Hazard ratios for myocardial infarction and all-cause mortality with 95% confidence intervals in 
relation to acute kidney injury stage defined by absolute increase in postoperative serum creatinine 
values*. 
 No AKI† Stage 1 Stage 2 Stage 3 
Number of patients (%) 24 312 (87) 1763 (6) 1209 (4) 645 (2) 
     
Myocardial infarction     
Number of MIs (%) 1691 (7) 181 (10) 166 (14) 81 (13) 
Multivariable adjustment‡ 1.00 1.35 (1.15–1.57) 1.80 (1.53–2.13) 1.63 (1.29–2.07) 
     
All-cause mortality     
Number of Deaths (%) 3532 (15) 427 (24) 402 (33) 318 (49) 
Multivariable adjustment‡ 1.00 1.30 (1.17–1.44) 1.65 (1.48–1.83) 2.68 (2.37–3.03) 
*Acute kidney injury classified according to absolute increase in serum creatinine values. Stage 1: 0.3–0.5 
mg/dL. Stage 2; 0.5–1 mg/dL. Stage 3; >1 mg/dL. AKI, acute kidney injury; MI, myocardial infarction.  
†Reference category.  
‡Multivariable adjustment was made for: age, sex, diabetes mellitus, estimated glomerular filtration rate, left 
ventricular ejection fraction, prior MI, heart failure or stroke.  	  
Sex-specific analysis showed that the relative risk for MI associated with AKI was similar 
in men and woman. When stratified by preoperative eGFR we saw a significant association 









The exclusion criteria of patients in study III are presented in Figure 1. Baseline 
characteristics of the population in Study II and Study III was similar (Table 7).  
	  
Outcomes 
During a mean follow-up period of 4.1 years, 1156 (4.9%) patients had a first stroke. Most of 
these, 73% were ischemic, 8% were hemorrhagic, and 19% unspecified. The mean time to a 
first stroke was 2.9 years. The risk of stroke increased with increasing AKI stage (Table 10). 
 
 
Table 9. Hazard ratios for myocardial infarction and all-cause mortality with 95% confidence intervals in 
relation to acute kidney injury stage defined by absolute increase in postoperative serum creatinine 
values* stratified by preoperative renal function in patients undergoing coronary bypass grafting. 
 Acute Kidney Injury Stage 
 No AKI† 1  2 + 3 
Myocardial infarction  HR (95% CI)‡ HR (95% CI)‡ 
GFR ≥60 mL/min/1.73 m2 1.00 1.37 (1.12–1.66) 1.82 (1.50–2.20) 
GFR 45–60 mL/min/1.73 m2 1.00 1.49 (1.09–2.04) 1.90 (1.44–2.50) 
GFR 15–45 mL/min/1.73 m2 1.00 1.11 (0.70–1.76) 1.40 (1.02–1.92) 
    
All-cause mortality    
GFR ≥60 mL/min/1.73 m2 1.00 1.29 (1.12–1.47) 1.95 (1.72–2.21) 
GFR 45–60 mL/min/1.73 m2 1.00 1.27 (1.04–1.56) 2.33 (1.99–2.73) 
GFR 15–45 mL/min/1.73 m2 1.00 1.35 (1.06–1.72) 1.68 (1.40–2.00) 
*Acute kidney injury classified according to absolute increase in SCr values. Stage 1: 0.3–0.5 mg/dL. Stage 2: 
0.5–1 mg/dL. Stage 3: >1 mg/dL.  
† Reference category. GFR was estimated by the Modification of Diet in Renal Disease study equation. 
AKI, acute kidney injury; GFR, glomerular filtration rate; HR, hazard ratio; CI, confidence interval.  
‡Multivariable adjustment was made for age, sex, diabetes mellitus, left ventricular ejection fraction, prior 
myocardial infarction, prior heart failure, and prior stroke.  





Table 10. Hazard ratios of first hospitalization for all strokes, ischemic or hemorrhagic stroke with 95% 
confidence intervals in relation to acute kidney injury, classified according to absolute increase in serum 
creatinine values*, in 23 584 patients undergoing primary isolated coronary bypass grafting, 2000–2008 
in Sweden. 
 Acute Kidney Injury Stage 
 No AKI† 1 2 3 
     
Number of patients 20 820 1404 944 416 
All strokes     
Number of events (%) 959 (5) 87 (6) 77 (8) 33 (8) 
Incidence rate (per 1000 PY) 11 (10–12) 16 (13–19) 21 (17–26) 23 (17–32) 
Multivariable adjustment‡ 1.00 1.12 (0.89–1.39) 1.31 (1.04–1.66) 1.31 (0.92–1.87) 
     
Ischemic stroke     
Number of events (%) 694 (3) 67 (5) 52 (6) 25 (6) 
Incidence rate (per 1000 PY) 8 (7–9) 12 (9–15) 14 (11–19) 17 (12 -25) 
Multivariable adjustment‡ 1.00 1.18 (0.92–1.52) 1.21 (0.91–1.61) 1.37 (0.91–2.05) 
     
Hemorrhagic stroke     
Number of events (%) 85 (0.4) 7 (0.5) 6 (0.6) 4 (1) 
Incidence rate (per 1000 PY) 1 (0.8–1.2) 1.2 (0.6–2.5) 1.6 (0.7–3.5) 2.6 (1–7) 
Multivariable adjustment‡ 1.00 1.02 (0.47–2.22) 1.13 (0.49–2.62) 1.75 (0.63–4.91) 
*Acute kidney injury (AKI) classified according to absolute increase in SCr values. Stage 1: 0.3–0.5 mg/dL. 
Stage 2: 0.5–1 mg/dL. Stage 3: >1 mg/dL.  
†Reference category.  
PY, person years. 
‡Multivariable adjustment was made for age, sex, preoperative estimated glomerular filtration rate, atrial 
fibrillation, diabetes mellitus, peripheral vascular disease, and preoperative heart failure.  
 
The cumulative incidence of stroke 5 years after CABG was 8.0% among patients in AKI 
stage 1, 9.9% in stage 2 and 11% in stage 3. After multivariable adjustment for confounders, 
only patients in AKI stage 2 had a significantly increased risk of stroke (Table 10). 
When AKIN criteria were used to classify patients with AKI, the associations were similar to 









Table 11. Hazard ratios of first hospitalization for all stroke, ischemic or hemorrhagic stroke with 95% 
confidence intervals in relation to acute kidney injury stage defined by the Acute Kidney Injury Network 
(AKIN) classification* in 23 584 patients undergoing primary isolated coronary artery bypass grafting in 
Sweden, 2000–2008. 
 No kidney 
injury† AKIN Stage 1 AKIN Stage 2 AKIN Stage 3 
Number of patients 20 810 2449 273 52 
All stroke     
Number of events (%) 959 (4) 175 (7) 18 (7) 4 (8) 
Incidence rate (per 1000 PY) 11 (10–12) 18 (16–21) 19 (12–30) 21 (8–56) 
Multivariable adjustment‡ 1.00 1.20 (1.02–1.42) 1.30 (0.81–2.07) 1.55 (0.58–4.15) 
     
Ischemic stroke     
Number of events (%) 694 (3) 127 (5) 14 (5) 3 (6) 
Incidence rate (per 1000 PY) 8 (7–9) 13 (11–16) 14 (9–24) 16 (5–48) 
Multivariable adjustment‡ 1.00 1.19 (0.98–1.45) 1.36 (0.80–2.32) 1.64 (0.53–5.11) 
     
Hemorrhagic stroke     
Number of events (%) 85 (0.4) 15 (0.6) 2 (0.1) 0 
Incidence rate (per 1000 PY) 1 (0.8–1.2) 1.5 (0.9–2.5) 2 (0-5–8) 0 
Multivariable adjustment‡ 1.00 1.15 (0.66–2.02) 1.58 (0.39–6.46) - 
*Acute kidney injury classified according to the Acute Kidney Injury Network classification. Stage 1: 0.3–0.5 
mg/dL or 50–100%. Stage 2: 0.5–1 mg/dL or 100–200%. Stage 3: >1 mg/dL or >200% increase from baseline.  
†Reference category. PY, person years. 
‡Multivariable adjustment was made for age, sex, preoperative estimated glomerular filtration rate, atrial 
fibrillation, diabetes mellitus, peripheral vascular disease, and preoperative heart failure.  
 
When patients were stratified by sex and AKI dichotomized yes (>26 µmol/L increase in 
postoperative SCr) or no (<26 µmol/L increase in postoperative SCr), we found that the 
association between AKI and stroke was significant for men but not for women. When we 
stratified patients by preoperative eGFR in subgroup analyses, we found a significant 
association between AKI and stroke in patients with eGFR >60 mL/min/1.73m2, but not 










Table 12. Hazard ratios of all stroke and a composite end-point of all stroke or death with 
95% confidence intervals in relation to acute kidney injury (yes/no), stratified by 
preoperative renal function in 23 584 patients who underwent primary isolated coronary 
artery bypass grafting in Sweden, 2000–2008. 
 Acute Kidney Injury 
 No* Yes 
All stroke  Hazard ratio (95% CI) 
GFR ≥60 mL/min/1.73 m2  1.00 1.26 (1.02–1.54) 
GFR 45–60 mL/min/1.73 m2 1.00 0.98 (0.70–1.36) 
GFR 15–45 mL/min/1.73 m2 1.00 1.26 (0.86–1.85) 
   
All stroke or death   
GFR ≥60 mL/min/1.73 m2 1.00 1.30 (1.17–1.44) 
GFR 45–60 mL/min/1.73 m2 1.00 1.56 (1.35–1.82) 
GFR 15–45 mL/min/1.73 m2 1.00 1.48 (1.23–1.77) 
*Reference category. Acute kidney injury was defined as a postoperative increase in creatinine 
>26 µmol/L (0.3 mg/dL) compared with preoperative creatinine. Multivariable adjustment was 
made for age, sex, atrial fibrillation, diabetes mellitus, peripheral vascular disease, and 
preoperative heart failure. Glomerular filtration rate was estimated by the Modification of Diet 
in Renal Disease study equation.  
 
Similarly, when we stratified into patients into those younger and older than 65 years and 
dichotomized those with and without AKI, we found a 57% increased risk for stroke among 
younger patients with AKI (HR: 1.57; 95% CI: 1.12–2.22).  
 
Composite end-point of death and stroke 
An association was found between AKI and the cumulative end-point stroke or death over 8 
years after undergoing CABG (Figure 4). When we dichotomized patients into presence or 
absence of AKI and calculated adjusted HRs for death or stroke, we found risk increased by 









Figure 4. Cumulative incidence of stroke or death in relation to the stage of acute kidney injury, classified 
according to absolute increase in serum creatinine values, in patients undergoing primary isolated coronary 
artery bypass grafting in Sweden from 2000-2008. 
 
Competing risk  
As death might be a competing risk for stroke, we analyzed the association between AKI and 
stroke with competing risk regression. The subhazard ratio for stroke was non-significant 




The population in Study IV was recruited from the SWEDEHEART register and included all 
patients who underwent a primary, isolated CABG during 2000 to 2008, in Sweden, for a 











Table 13. Baseline characteristics by level of acute kidney injury according to the Acute Kidney Injury 
Network classification*. 
  Acute Kidney Injury stage 
 All patients 0 1 2 and 3 
Number of patients (%) 29 330 (100) 25 609 (87) 3159 (11) 562 (1.9) 
Age (SD), years 67.0 (9.2) 66.5 (9.2) 70.5 (8.8) 69.7 (9.2) 
eGFR mL/min/1.73 m2, %     
eGFR >60  80 83 63 62 
eGFR 45–60  15 14 23 18 
eGFR 30–45  4.2 3.1 12 10 
eGFR 15–30  0.9 0.4 2.7 11 
Female sex, % 21 21 20 23 
eGFR (SD), mL/min/1.73 m2  77 (21) 78 (20) 69 (23) 71 (33) 
Preoperative SCr (SD), µmol/L 92 (26) 90 (22) 104 (34) 114 (65) 
EuroSCORE (SD) 3.9 (2.5) 3.7 (2.4) 4.9 (2.5) 5.2 (2.7) 
Diabetes mellitus, % 23 22 31 32 
Prior hospitalization for CHF, % 3.7 3.2 7.1 7.3 
Left ventricular function, %     
Ejection fraction >50%  70 71 62 55 
Ejection fraction 30–50%  26 25 32 38 
Ejection fraction <30%  3.7 3.3 5.8 7.8 
Internal thoracic artery use, % 94 94 94 94 
CABG without cardiopulmonary bypass, % 5.4 5.2 6.4 7.5 
SD, standard deviation; eGFR, estimated glomerular filtration rate; SCr, serum creatinine; CHF, congestive heart 
failure; CABG, coronary artery bypass grafting. Age, eGFR, serum creatinine, and EuroSCORE values are given 
as means with standard deviations. 
*Classification system for acute kidney injury. Serum creatinine criteria. Stage 1: Increase in serum creatinine of 
≥0.3 mg/dL (≥26.4 µmol/L) or increase to ≥150–200% from baseline. Stage 2: Increase in serum creatinine to 
>200–300% from baseline. Stage 3: Increase in serum creatinine to >300% from baseline (or serum creatinine of 
≥4.0 mg/dL [≥354 µmol/L] with an acute increase of >0.5 mg/dL [44 µmol/L]). Patients who receive renal 
replacement are considered to have met the criteria for stage 3. 
 
We excluded 9969 patients whose SCr information was missing (Figure 1), although their 1-, 










End-stage renal disease and mortality 
During a mean follow-up period of 4.3 years, 123 (0.4%) patients developed ESRD. The 
mean age of these patients when they started dialysis/were transplanted was 68 ±10 years. 
They had lower eGFRs, were more frequently diabetics and had reduced LVEF more often 
than patients who did not develop ESRD. Among patients without AKI, 0.2% (44) developed 
ESRD during follow-up. Among patients with AKI, 1.6% (50) of those at AKIN stage 1, and 
5.2% (29) at AKIN stages 2–3, started treatment for ESRD during follow-up (Table 14). 
After multivariable adjustment for all baseline characteristics in Table 13, HR for ESRD 
among patients at AKIN stage 1 was almost three times higher, and the risk for patients 
without AKI (Table 14). For patients at AKIN stages 2–3, the risk was almost four times 
higher. 
 
Table 14. Association between acute kidney injury, using the Acute Kidney Injury Network (AKIN) 
classification* and risk for end-stage renal disease (ESRD) and ESRD or death in 29 330 patients 
who underwent primary isolated coronary artery bypass grafting in Sweden, 2000–2008. 
 0† AKIN Stage 1 AKIN Stage 2 and 3 
Number of patients (%) 25 609 (87) 3159 (11) 562 (1.9) 
ESRD    
Number of events (%) 44 (0.2) 50 (1.6) 29 (5.2) 
Multivariable adjusted‡ HR (95% CI) 1.00 2.92 (1.87–4.55) 3.81 (2.14–6.79) 
ESRD + death    
Number of events (%) 3554 (14) 840 (27) 216 (38) 
Multivariable adjusted‡ HR (95% CI) 1.00 1.34 (1.23–1.45) 2.32 (2.01–2.68) 
*Classification system for acute kidney injury. Serum creatinine (SCr) criteria. Stage 1: Increase in SCr of 
≥0.3 mg/dL (≥26.4 µmol/L) or increase to ≥150–200% from baseline. Stage 2: Increase in SCr to >200% 
to 300% from baseline. Stage 3: Increase in SCr to >300% from baseline (or SCr of ≥4.0 mg/dL [≥354 
µmol/L] with an acute increase of at least 0.5 mg/dL [44 µmol/L]). Patients who receive renal replacement 
are considered to have met the criteria for stage 3. HR, hazard ratio 
†Reference category. All P-values for Acute Kidney Injury stage 1 and 2–3 vs. AKI stage 0 were <0.001. 
‡Multivariable adjustment was made for all variables in Table 13.  
 
 
Figure 5 describes the cumulative incidence of ESRD, taking death into account as a 
competing event. The cumulative incidence of ESRD increased as AKIN stage advanced.	  





Figure 6 describes the cumulative incidence of the combined outcome of ESRD and death 
during 8 years of follow-up. 
Figure	  5.	  Cumulative incidence of end-stage renal disease using the Acute Kidney Injury Network 
(AKIN) classification of acute kidney injury (AKI) in 29 330 patients who underwent primary isolated 
coronary artery bypass grafting in Sweden, 2000–2008.	  
 
 
Figure 6. Cumulative incidence of end-stage renal disease or death, using the Acute Kidney Injury 
Network (AKIN) classification for acute kidney injury (AKI) in 29 330 patients who underwent primary 








In a subgroup analysis, we stratified patients by preoperative renal function. The adjusted HR 
for ESRD, among patients with AKI compared with patients without AKI, is shown in Table 
15. Patients with a normal preoperative eGFRs who developed AKI postoperatively had a 
six-fold increase in risk of developing ESRD during follow-up. The risk for development of 
ESRD was higher among patients with preoperative eGFR >60 mL/min /1.73m2 than among 
patients with worse eGFRs. The corresponding HR for ESRD and death in different groups of 
preoperative kidney function showed increased risk for developing ESRD of 30–70% in all 
patients with AKI, compared with patients without AKI (Table 15). 
 
Table 15. Association between acute kidney injury (yes/no) and end-stage renal disease (ESRD) and 
ESRD or death stratified by preoperative renal function in 29 330 patients who underwent primary 
isolated coronary artery bypass grafting during 2000 to 2008 in Sweden. 
 Acute Kidney Injury 
 No* Yes 
ESRD  Hazard Ratio (95% CI) 
GFR ≥60 mL/min/1.73 m2 1.00 6.24 (1.94–20.1) † 
GFR 45–60 mL/min/1.73 m2 1.00 4.54 (2.00–10.3) † 
GFR 15–45 mL/min/1.73 m2 1.00 3.48 (2.17–5.57) † 
   
ESRD or death   
GFR ≥60 mL/min/1.73 m2 1.00 1.32 (1.19–1.46) ‡ 
GFR 45–60 mL/min/1.73 m2 1.00 1.72 (1.50–1.98) ‡ 
GFR 15–45 mL/min/1.73 m2 1.00 1.55 (1.32–1.83)‡ 
Acute kidney injury was defined as Acute Kidney Injury Network stage 1 or higher. GFR was estimated by the 
Modification of Diet in Renal Disease study equation. There was no evidence for a significant renal function by 
acute kidney injury interaction for the outcomes ESRD (P=0.523) or ESRD/death (P=0.080).  
*Reference category  
†Multivariable adjustment was made for age, sex, diabetes, and peripheral vascular disease.  
‡Multivariable adjustment was made for age, sex, diabetes, peripheral vascular disease, left ventricular function, 
chronic obstructive pulmonary disease, atrial fibrillation, history of heart failure, prior myocardial infarction, 
prior stroke, and use of an internal mammary artery. 
 
When patients were stratified for sex, adjusted HR for ESRD was 2.97 (95% CI: 1.85–4.78) 
in men and 3.51 (95% CI: 1.46–8.40) in women.  
 
 









Through epidemiologic research, we can describe the occurrence of diseases, the effects of 
treatments, and compare treatments and preventive actions. All epidemiological studies are 
affected by systematic error (bias) and random error to some extent, but if the researcher is 
aware of this, the effects of bias can be handled and their influence can be minimized.  
	  
Study	  design	  
For an epidemiologist, studying the entire world’s population would be fantastic, but of 
course, this is not possible. Instead, the epidemiologist must define a group of individuals 
who are representative of the background population. There are different types of 
epidemiological study designs. They can be divided into two main types; intervention 
(experimental) and observational (descriptive or analytic) studies. Interventional studies, i.e., 
Randomized Clinical Trials (RCTs) are considered superior to other types of studies because 
of the control of the exposure and preferably an even distribution of confounders in both 
exposed and non-exposed subjects. However, well-designed observational studies have been 
shown to be at least as valid as randomized trials.153, 154 Furthermore, conducting a RCT is not 
possible in some situations. In addition, RCTs are associated with high costs. In Sweden, we 
have numerous registers with high validity, and our unique personal identity numbers 
facilitate gathering and merging information from several registers into a study cohort.  
Observational studies can be further divided into longitudinal and cross sectional studies, 
which in turn represents case-control, cohort and ecological studies. This thesis contains 








Another word for systematic error is ‘bias’, meaning ‘deviation from the truth’.155 Bias is not 
dependent on chance, but rather reflects shortcomings in the study design. Bias can be 
divided into selection bias, information bias and confounding. Different types of bias affect 
the internal validity of a study. Systematic error cannot be handled by increasing the size of 
the study population. Only a well-designed study can reduce the effect of systematic error. 
Since observational studies aren’t randomized, with equal distributions of patients within 
different groups, considering other explanations that can affect the results is essential.156 
 
Selection	  bias	  
Selection bias is a systematic error that causes difficulties when subjects included in the study 
differ from those not included and can lead to over- or underestimation of the true relative 
risk.156 In retrospective cohort studies, bias can arise if the study population is not well 
defined and individuals are excluded because of death or emigration before the beginning of 
follow-up. 
In Study I, the study population was collected from a local register at the Karolinska 
University Hospital in Solna. Patients with missing SCr values were excluded from the study. 
Bias could be introduced if patients with missing SCr values were different from those with 
information on SCr values. We investigated the mortality among these individuals and found 
no difference in mortality.  
 
Information	  bias	  
Information bias is another type of systematic error. It is also called observation, 
classification, or measurement bias. It arises when information gathered from or about the 
study participant is incorrect.156 An example of this misclassification would be an exposed 
patient with AKIN stage 3 being classified as having AKIN stage 1, in a study that used 
exposure as a defined category. Misclassification of study participants for either exposure or 
disease can be further divided into differential and non-differential misclassification. 
Differential misclassification arises when the misclassification of exposure is different for 
those with, compared to those without the disease. Misclassification is non-differential if it is 
unrelated to exposure; that is, the misclassification arises among both exposed and unexposed 





subjects.156 Thus non-differential misclassification tends to reduce differences between 
groups, whereas differential misclassification tends to over-or underestimate their 
differences.155, 156 
Information bias can also be introduced when patients with missing values are excluded from 
a study. As an example, 26% of the patients in our cohort had missing information on DM. 
After multiple imputation of this variable, we found similar HRs for outcomes in question in 
groups with and without information on DM, which indicates that the missing information on 
DM was missing at random. 
 
Potentially, AKI has a risk of misclassification in all our studies. AKIN, RIFLE and absolute 
increase of SCr all depend on changes in SCr, but SCr is a surrogate marker for kidney injury. 
It is a marker for kidney function, but altered kidney function can be a physiological 
response, rather than a reflection of pathology; SCr can be increased by causes other than 
AKI. An example is hypovolemia, which can lead to a misclassification; a patient might be 
classified as having AKI if volume depletion (rather than kidney injury) is causing higher SCr 
levels. Another common origin of AKI misclassification among patients with missing 
baseline SCr levels is estimating SCr by the patients’ weight and age, using the MDRD 
formula.28 This method was not used in any of the studies included in this thesis; instead we 
excluded patients with missing baseline SCr levels. We also analyzed baseline characteristics 
of patients in Study IV with missing baseline information about SCr, post-operative SCr and 
DM status, in terms of 1-, 5-, and 10-year survival, and found no differences. So by excluding 
patients with missing SCr we have most probably not introduced any misclassification in the 
study. Since the study cohort is virtually the same in Studies II, III and IV, these results 
should be applicable to these studies as well.  
Some outcomes in our studies might have been misclassified. Overall mortality as an 
outcome is hard to misclassify, as it is an irreversible state and virtually no information 
concerning death is missing, whereas MI and stroke outcomes in Studies II and III have some 
possibility of misclassification. Diagnosis of MI in Sweden has been evaluated in several 
studies and shown to have a high validity.148, 157 Diagnosis of stroke as the principal cause of 
hospitalization has a positive predictive value of 94%.158 Despite high quality registers, some 
patients may suffer misclassified MIs, strokes or transitory ischemic attacks, leading to bias 








A confounder is a factor that is associated with both the exposure and the outcome studied 
(Figure 7.). It can be described as “confusion of effects”.156  
 






A major task in epidemiologic studies is controlling for confounding factors, which may be 
done by several methods, including randomizing, matching or restriction of study subjects, or 
stratifying or adjusting for confounders in multivariable regression analysis.156 Confounding 
was controlled by using multivariable regression analyses in the studies in this thesis. 
In study I, we had no information on smoking status, which could be a potential confounder. 
In general surgery, smoking is known to lead to adverse postoperative outcomes, such as 
impaired wound healing and increased mortality risk, whereas smoking cessation reduces 
postoperative adverse outcomes.159 The same principle might be supposed of wound healing 
in CABG patients as in patients undergoing general surgery. Studies of smoking habits and 
cardiac surgery outcomes are limited, but increased risk for sternocutaneous fistulas and 
mediastinitis after sternal incision has been reported for smokers.160 Other risk factors for 
mediastinitis are obesity and DM, for which we adjusted for in multivariable analysis.160, 161  
We had no information on the use of intra-aortic balloon pumps, which potentially may 
have affected our results. However, as we excluded patients undergoing emergency surgery, 
this is unlikely to have affected our results. Another potential confounding factor could be 
operation time and cross clamp time, which we did not have information about. However, we 
Exposure Outcome 
Confounder 





had information on number of peripheral anastomoses, which was not associated with the 
exposure or the outcome. 
All our studies may be influenced by residual confounding factors not known to us. For 
example, we did not have information on preoperative proteinuria, some patients may have 
had normal eGFR with proteinuria. Another confounding factor in our studies might be the 
absence of information on potential nephrotoxic drugs such as NSAIDs or ACE inhibitors, 
which might affect the risk of AKI. 
 
Random	  error	  
Random error is the influence of chance. It affects the precision of estimates and is present in 
all studies. Random error is inversely proportional to sample size; increasing sample size 
tends to reduce random error. We used P-values and CIs to address the effect of random 
error. Confidence interval gives a range which is likely to include the true population value. 
P-values show the probability that the observed value is based on chance, given that the null 
hypothesis is true. If the P-value is set to <0.05, it means that there is less than 5% risk that 
our estimate is caused by chance.156 A non-significant P-value doesn’t necessary mean that 
the null hypothesis is true; the results should always be interpreted with caution.  
 
External	  validity	  
External validity or generalizability is the ability to apply results from one study to other 
cohorts, in other cities or countries than where the study was conducted. So what is the 
external validity of our studies? Our first study is a single-center study among patients who 
underwent primary isolated CABG, which may have affected its external validity. In Studies 
II–IV, the cohort consisted of all patients who underwent non-emergent CABG all over 
Sweden. However, our cohort is similar to other cohorts of patients undergoing CABG in 
both the United States and United Kingdom, in terms of ages and comorbidities,14, 162 
therefore we believe that our results are generalizable to other hospitals in other countries, 








As this thesis is based on epidemiological studies, we studied AKI as exposure and 
investigated its association to different outcomes. We were not able to distinguish whether 
AKI caused the outcomes, or was merely a marker for increased risk of adverse outcome.  
Few RCTs have addressed this subject but several epidemiological studies suggest an 
association between AKI and ESRD.82, 163, 164 There are also some studies on animal models 
that suggest a causal relationship between AKI and long-term worsening of kidney function 
caused by microvascular damage, reduced capillary density, and chronic renal hypoxia.165-167 
In 2014, Garg et al. published a RCT that evaluated the association between AKI and kidney 
function 1 year after on- or off-pump CABG. Acute kidney injury was defined as a 
postoperative increase of SCr levels by >50% compared with preoperative levels. Fewer 
patients operated off-pump (18%) developed postoperative AKI than did patients operated 
on-pump (21%). However, at one year, the groups did not differ in kidney function.168 This 
suggests that AKI is a marker for an increased risk of worsening of renal function rather than 
a causative factor in itself. 
Several studies show a strong association between AKI and CKD; however, the RCT by Garg 
et al. found no difference between AKI and non-AKI patients after one year.168  
However, the mechanism behind AKI and its relation to ESRD development is most likely 
multifactorial. It can be a proxy for a more complicated postoperative course or a more 
vulnerable group of patients with more advanced arteriosclerosis. The surgery can affect the 
kidneys and speed up and exacerbate decline in kidney function over time. AKI and ESRD 
also share several risk factors, including DM, older age, and hypertension.  
 






INTERPRETATION	  OF	  FINDINGS	  
 
STUDY	   I:	   EARLY	   MORTALITY	   AND	   POSTOPERATIVE	   COMPLICATIONS	   IN	  
RELATION	  TO	  AKI	  AFTER	  CABG	  
In Study I, we investigated the effect of AKI in postoperative complications and mortality 
within 60 days of a first isolated CABG. The 14% of these patients who were affected by 
AKI had increased mortality of more than 4 times that of patients without AKI. The risk for 
postoperative complications was also strongly associated with AKI.  
The reported incidence of AKI in cardiac surgery patients varies from about 9% to 39%, 
depending on type of cardiac surgery, classification of AKI, and patient population.61, 169, 170 
Compared with other studies of patients who underwent non-emergent CABG, the incidence 
in our cohort is in the lower range, 14%. In another study by Li et al., AKI incidence was 
20%, which may have been caused by 56% of the study population being diabetic, compared 
with 20% in our study. Their study population was also older. Furthermore, patients with 
dialysis-dependent renal failure were not excluded and baseline eGFR was lower than in our 
population.43 In other cohorts of CABG patients in the United States, and United Kingdom 
AKI incidence was 11% and 12%, respectively. Even increases less than 26 µmol/L in 
postoperative SCr levels have been associated with early adverse outcome in a few studies.20, 
171, 172  
When we compared the predictive ability of AKI classified by AKIN and RIFLE, AUCs 
were 0.77 for AKIN 1 and 0.66 for RIFLE R (P <0.01), indicating that AKIN is a better 
predictor of death in the short term than RIFLE. 
Our data indicate that even very small increases in postoperative SCr levels should be taken 







STUDY	   II:	   ACUTE	   KIDNEY	   INJURY	   FOLLOWING	   CABG	   AND	   LONG-­‐TERM	  RISK	   OF	  
MYOCARDIAL	  INFARCTION	  AND	  DEATH	  
In Study II we found a strong association between AKI and MI during a mean follow-up 
period of 5 years. Also, mortality during follow up was markedly increased, up to >3 times 
among patients with AKI stage 3. Our results are consistent with another study of patients 
who underwent primary isolated CABG, where AKI (as defined by RIFLE) was present in 
12% of the study population and all-cause mortality rate was 22% among patients in RIFLE 
stage 1 at 5 years after surgery.173 Hobson et al. presented a much higher incidence of AKI 
among isolated CABG patients—37% according to RIFLE—but the 5-year mortality among 
patients without AKI were similar, 14% among all patients who underwent cardiac surgery 
and 15% in our study.45 Li et al. studied elective CABG patients and classified AKI 
according to AKIN. After 5 years, 20% of patients in AKIN stage 1 had died, as did ~40% of 
those in AKIN stage 2, and all patients in AKIN stage 3. Notably, 12% of the patients were 
older than 80 years, and 35% were older than 75 years, which might have contributed to the 
high mortality rates.  
During follow-up, 2119 patients (7.6%) presented with MI. We found AKI stage 1 through 3 
to be associated with a 35% to 63% increased risk of MI. In other studies concerning survival 
after CABG and cardiac events, without knowledge on AKI, the incidence of MI and all-
cause mortality is slightly higher than ours.174, 175 To the best of our knowledge, no previous 
study has investigated the association between MI and AKI. Although unknown confounders 
might cause part of the association, after controlling several important confounders, risk for 
MI among patients with AKI after CABG increased by 35% in AKI stage 1 compared with 
patients without AKI. This patient category might benefit from close surveillance by a 
cardiologist postoperatively to optimize all modifiable factors to prevent future 
cardiovascular disease. 
 
STUDY	  III:	  ACUTE	  KIDNEY	  INJURY	  AND	  LONG-­‐TERM	  RISK	  OF	  STROKE	  AFTER	  CABG	  	  
 
Study III investigated the effect of AKI after CABG on long-term risk of stroke. We found a 
weak association between AKI and stroke, but the association disappeared after taking death 
into account as a competing risk. 





As this cohort is generally the same as in Study II the overall incidence of AKI was 12%. The 
incidence of stroke during follow-up was almost 5%. In a previous study of patients treated 
with in-hospital dialysis, Wu et al. found increased risk of stroke over 3.4 years of follow-up, 
of 6.6 per 1000 person-years compared with 11.5 per 1000 person-years among patients 
without need of in-hospital dialysis.176 These numbers are in line with our results. 
 A possible explanation of the pathogenesis linking kidney injuries to strokes has been 
described in a mouse model. Ischemic AKI was shown to cause damage of the blood–brain 
barrier and increase microvascular permeability in the brain and induction of pro-
inflammatory chemokines.177 Although the association between AKI and stroke disappeared 
after competing risk analysis, an association was seen between AKI and stroke among 
patients under the age of 65 years in age-stratified analysis.  
Studies I, II and IV, as with many other studies on the subject, present significant associations 
between AKI and adverse outcomes—mainly short- and long-term mortality and risk for MI 
and ESRD. Interestingly, this study is not in line with those results, which might reflect 
different pathophysiological associations between those outcomes and cerebrovascular 
events. As discussed earlier, pathophysiological changes are found in mice with AKI and 
significant association is found among general hospitalized patients with dialysis-dependent 
AKI.176, 177 A possible explanation is that this reflects competing insults, as patients develop 
stroke later in life (mean respective ages: 74 and 80 years for men and women), compared 
with MI (62 and 73 years) and may thus die before developing a cerebral insult.178, 179 
 
STUDY	   IV:	  ACUTE	  KIDNEY	   INJURY	  FOLLOWING	  CABG	  AND	  LONG-­‐TERM	  RISK	  OF	  
END-­‐STAGE	  RENAL	  DISEASE	  
Study IV investigated the effect of AKI after a first isolated CABG and development of 
ESRD. We found a strong association between AKI and development of ESRD that persisted 
after adjustment for several confounders. Among patients with AKIN 1 the HR for ESRD 
was more than twice that of patients without AKI, and tripled for patients with AKIN 2–3. 
Incidence rate of ESRD was 0.40 (95% CI: 0.30–0.53) per 1000 person-years among patients 
without AKI and 3.68 (2.79–4.86) and 13.2 (9.14–18.9) among patients in AKIN 1 and 2+3 
combined.  
No studies are available on ESRD development in patients with AKI who have undergone a 






development of ESRD has been described in several other clinical settings.163, 180 In a large 
cohort of patients with AKI after coronary angiography, risk of developing ESRD increased 
in those with AKIN 1 by 60% and by >11-fold in those with AKIN 2+3.181 Among a 
population of general hospitalized patients with AKI that required dialysis, risk of ESRD 
after 5 years increased >6-fold than in patients with AKI who didn’t require dialysis during 
hospital admission.182 Five-year incidence of ESRD was 0.3% among patients without 
dialysis-dependent AKI and 3.8% among patients who had dialysis during hospitalization.182  
Several studies in different clinical settings, especially those with large cohorts of patients 
similar to ours, who underwent coronary angiography, show increased risk for ESRD among 
patients with AKI, even in its mildest form. The mechanism behind the association is not 
known, but could reflect an accelerating effect of AKI on decreasing kidney function as part 
of the ageing process or on other pathways that lead to impaired ultrafiltration, or it could be 
a proxy for a more vulnerable category of patients with increased risk for ESRD. 
Dialysis is life-saving for patients but very physically and psychologically demanding. It is 
also associated with high health care costs and high annual risks of morbidity and mortality. 
These patients should be under close surveillance of a nephrologist who can take every 
necessary action to prevent or delay the progression of kidney failure. 
 









• Acute kidney injury after CABG, including small changes of serum creatinine is 
associated with postoperative complications and mortality within 60 days of surgery. 
 
• Acute kidney injury after CABG is strongly correlated with long-term all-cause 
mortality and increased long-term risk for myocardial infarction. 
 
• We found a weak association between AKI and stroke after CABG, but the 
association disappeared after taking death into account as a competing risk. 
 
• Acute kidney injury after CABG is correlated with increased long-term risk for end-
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